<DOC>
	<DOCNO>NCT02710214</DOCNO>
	<brief_summary>Duavee hormone receptor modulator approve treatment menopausal symptom menopausal woman . The goal 8-week randomize , double blind , placebo control pilot study , determine whether medication alleviates menopausal symptom woman MS . The investigator secondarily determine whether address menopausal symptom ameliorate MS symptom , MRIs , trigger worsen inflammation .</brief_summary>
	<brief_title>A TSEC Symptom Management Menopausal Women With Multiple Sclerosis</brief_title>
	<detailed_description>Menopause MS . Multiple sclerosis ( MS ) affect 3 time woman men , age 50 90 % case , i.e . prior menopause . There broad evidence hormonal regulation MS animal model clinical cohort . Around menopause , many clinical patient report symptom worsen associate hot flash , sleep disturbance mood change . Additionally , individual MS may increase risk develop osteoporosis . Longer-term , age-related decline gonadal steroid might represent one sex-specific influence know age-related increase disability conversion progressive course , mark accelerated brain volume loss neurodegeneration . Recent data suggest MS disease severity may worsen menopause . - Hormone therapy ( HT ) . In healthy woman , abrupt decline estradiol occur early oophorectomy , increase risk cognitive decline dementia gray matter ( GM ) loss functionally important region ( e.g . hippocampus ) . Hormonal therapy ( HT ) , take within perimenopausal `` window opportunity '' ( 5 year ) , may protect neurodegeneration . Despite benefit HT ( menopausal symptom , bone density ) , woman ( &lt; 30 % cohort ) currently take HT menopausal symptom ; result risk ( 1 ) breast endometrial cancer , ( 2 ) stroke old woman Women 's Health Initiative . To date , objective assessment impact HT MS disease course . - Study Drug . Duavee , tissue selective estrogen complex ( TSEC ) , combine conjugate estrogen ( CE ) selective estrogen receptor modulator ( SERM ) bazedoxifene ( BZA ) . BZA offset estrogenic stimulation endometrial breast tissue , CE 0.45mg/BZA 20mg approve menopausal symptom ( hot flash ) relief osteoporosis prevention , favorable tolerability safety profile . Additionally , two recent randomize clinical trial estrogenic compound MS [ estriol ( Voskuhl et al ) ethinylestradiol 40 μg desogestrel 125 μg ( Pozzili et al 2015 ) find either neutral beneficial effect inflammatory outcome . Altogether , finding suggest CE+BZA may promise safe agent MS . In current study , 24 woman MS experience bothersome menopause symptom enrol randomized receive either 8 week Duavee 8 week placebo . Visits : eligibility , baseline , 2 month visit .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Women age 4062 year . Perimenopausal : 6 month amenorrhea Women bilateral oöphorectomy Women without uterus still one ovary , FSH level &gt; 20 mIU/mL estradiol ≤ 50 pg/mL Women uterus skip 2 menstrual cycle amenorrhea interval Women use Mirena IUD endometrial ablation still one ovary , FSH level &gt; 20 mIU/mL estradiol ≤ 50 pg/mL mean two hot flashes/night sweat per 24 hr Hot flashes/night sweat rat bothersome ( 'moderately ' ' lot ' ) and/or severe ( 'moderate ' 'severe ' ) 4 12 hour ( day/night ) block time In general good health ( determined medical history , blood pressure , heart rate ) No history endometrial , ovarian , breast cancer No abnormal mammogram last 2 year Absence current severe unstable medical illness MS consideration : If use psychotropic medication : change past 3 month If DMT , change past 6 month Normal vitamin D level ( 2050 ng/mL ) BMI &gt; 30 kg/m2 high BMI may affect PK/PD Use hormone therapy hormonal contraceptive 2 month prior enrollment Use prescribe therapy take specifically hot flash past 1 month . Use overthecounter herbal therapy take specifically hot flash past 2 week . Use selective estrogen receptor modulators ( SERMs ) aromatase inhibitor 2 month enrollment . Known hypersensitivity contraindication estrogen . Drug alcohol abuse past 1 year Depression : moderate severe ( HAD score &gt; 8 ) Other psychiatric disease meeting DSMIV criterion Lifetime diagnosis psychosis bipolar disorder . Pregnancy , intend pregnancy , breast feed History follow , determined clinician review potential participant 's medical history : Prebreast cancer highrisk breast cancer condition ; Abnormal bleed suggestive endometrial precancer ; Endometrial hyperplasia . Asthma , diabetes mellitus , epilepsy , migraine disorder stable medical management Active past history venous arterial thromboembolism History gallstone IF gallbladder intact Known suspect estrogendependent neoplasia History coronary artery disease Hypersensitivity ( angioedema , anaphylaxis ) estrogens , bazedoxifene , ingredient Known hepatic impairment disease Thyroid dysfunction thyroid medication Known hypoparathyroidism Blood test result indicate : Liver function test : AST &gt; 2.5 time upper limit normal ; ALT &gt; 2.5 time upper limit normal ; total bilirubin 1.5 time upper limit normal ; Kidney test : creatinine &gt; 1.5 mg/dL ; Blood count : hematocrit &lt; 30 % ; Hemoglobin &lt; 8 g/dL . Current participation another drug trial intervention study . Inability unwillingness complete study procedure . MS consideration : Clinical relapse within last three month ( ensure disease stability ) Steroid treatment prior 1 month Evidence structural brain disease ( e.g . prior stroke ) MRI consideration : Left hand Metal implant Prior head trauma Claustrophobia require anxiolytic sedation , contraindication MRI .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>62 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hot flash</keyword>
	<keyword>Estrogen</keyword>
	<keyword>Women</keyword>
</DOC>